1
NEW DE ON PRE 5 OCTO The 1st G Partnersh the backg • A m • A su • A st • A na 2) re an us Therefore • E ba • P m • A in • A ac an an ELHI CALL ESERVING BER, 2011 Global Forum hip to address ground of incr Antibiotics - a medicine; their Antibiotic resi uffering and d Antibiotic resi tatus or geogr Antibiotic resi ational comm ) ensure acces egulation to e ntibiotic use p se of antibiot e, we call for Extend access acterial infect revent as man measures. Achieve a bala nterventions t Advocate for a cademia, the p nd the wider ntibiotics and L TO ACTIO THE POWE m on Bacterial the challenge reasing drug r precious, life r usefulness m stance increa death around stance is a cri raphy. stance require mitments and ss to appropr ensure drug qu patterns, 5) st tics in animal action to: to effective a tions. ny infections ance within ou to reduce unn a global respo pharmaceutic health care co d use them eff ON ER OF ANT Infections ha e of insufficie resistance glo e-saving, com must be prese ses the preval the world. itical global c es an immedi including me riate drug pre uality, 4) imp timulate R&D feed for grow antibiotics to as possible th ur own count necessary use. onse supporte cal industry, p ommunity, sh fectively whe TIBIOTICS as been conv ent antibiotic obally. We her mmon propert erved to prote lence and sev oncern that a iate, sustained easures to 1) p scribing, disp plement surve D for new ant wth promotio those who w hrough vaccin tries between . ed by nationa professional a haring inform n they are ne ened by the G access in ma reby recognis ty resource - a ect human an verity of bacte affects all cou d, multi-secto prevent bacte pensing and u eillance for res tibiotics and 6 on. would otherwi nes, infection access to eff al government associations, c mation and str eded. Global Antibi ny developin se that: are a bedrock nd animal heal erial infection untries regardl oral, global res erial infection use, 3) strengt sistant bacter 6) discourage ise be ill or di n control and fective antibio ts, internation consumer and rategies, to red iotic Resistan g countries ag k of modern lth. ns, and adds t less of econo sponse based ns and their sp hen and enfo ria and for sub-therapeu ie from severe other proven otics and nal organizati d advocacy gr duce the need nce gainst to mic d on pread orce utic e n ions, roups d for
